For research use only. Not for therapeutic Use.
Vemtoberant is an β3 Adrenergic Receptor antagonist. Vemtoberant can be used for research of β3 adrenergic receptor-mediated disorder, such as, heart failure[1][2].
| Catalog Number | I041960 |
| CAS Number | 2169905-68-2 |
| Synonyms | 1-ethyl-3-[[(3R)-3-[[(2S)-2-hydroxy-3-(3-methylsulfonylphenoxy)propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]sulfonyl]quinolin-4-one |
| Molecular Formula | C29H37N3O8S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C29H37N3O8S2/c1-3-31-18-27(28(34)25-9-4-5-10-26(25)31)42(37,38)32-13-11-29(12-14-32)16-21(19-40-29)30-17-22(33)20-39-23-7-6-8-24(15-23)41(2,35)36/h4-10,15,18,21-22,30,33H,3,11-14,16-17,19-20H2,1-2H3/t21-,22+/m1/s1 |
| InChIKey | PVXLIOIISUUKOQ-YADHBBJMSA-N |
| SMILES | CCN1C=C(C(=O)C2=CC=CC=C21)S(=O)(=O)N3CCC4(CC3)CC(CO4)NCC(COC5=CC(=CC=C5)S(=O)(=O)C)O |
| Reference | [1]. WHO Drug Information-World Health Organization (WHO). [2]. Tran Thuy-Anh, et al. Preparation of modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto: World Intellectual Property Organization, WO2017214002. 2017-12-14. |
